Epidemiology and Histopathology of Breast Cancer in Iran versus Other Middle Eastern Countries
Journal Title: Middle East Journal of Cancer - Year 2018, Vol 9, Issue 3
Abstract
Background: Breast cancer is the most prevalent cancer among females worldwide. This study compares the results of the most cited published Iranian studies and studies from other Middle East countries on breast cancer with data from the Ministry of Health and Medical Education and approximately 2000 cases from the Cancer Research Center of Shahid Beheshti Medical University of Iran. Methods: Data from the Cancer Registry System of the Ministry of Health and Medical Education and the Cancer Research Center were obtained in addition to data from other published Iranian articles to increase the accuracy of incidence, prevalence, disease burden, risk factors, clinical staging, clinical pathology, biological markers, clinical subtypes, and survival rate of breast cancer in the last decade and compare the epidemiological data with other areas of the world. Results: Overall, breast cancer was the most common cancer in Iran. The agestandardized rate for breast cancer was 33.21 per 100,000 according to the latest national databases. The mortality rate for breast cancer has not changed in the past 30 years in Iran. The age-standardized rate for mortality was 14.2 per 100,000 with a mean age of 49.84 years. The most common cancer in Iran is invasive ductal carcinoma. In our last review, 65.5%-70.5% of cases were in the early stages (1 and 2) and less than 30% were in the advanced stages. The five-year overall survival rate was estimated at 72% in women and 60% in men. The stage and number of positive lymph nodes significantly affected the survival rate. In the Gulf Cooperation Council, ASR of the Kingdom of Saudi Arabia was (12.9), Bahrain (46.4), Kuwait (44.3), Qatar (35.5), United Arab Emirates (19.2), and Oman (14.4) per 100,000. Conclusion: Our study shows that epidemiology and histopathology of cancer is different with other neighborhood countries and is multi-dimension and needs multicenter involvement from government authorities, clinicians and scientists.
Authors and Affiliations
Nahid Nafissi, Maryam Khayamzadeh, Zahra Zeinali, Davood Pazooki, Mostafa Hosseini, Mohammad Esmaeil Akbari
Keywords
Related Articles
- EP ID EP303090
- DOI -
- Views 72
- Downloads 0
IL-35 Serum Levels in Bladder Cancer Patients: An Analytical Cross-sectional Study
Background: Bladder cancer is a prevalent disease with significant health care costs and high rates of recurrence. Results from numerous studies to associate bladder cancer with serum biomarkers have been analyzed for pr...
Global Inequalities in Cervical Cancer Incidence and Mortality
Objective: Cervical cancer (CC) is the third most common cancer in women after breast and colorectal cancers and is one of the leading causes of cancer death among women in the world. The aim this study is associations o...
Metastatic Urothelial Tumor Progression Following First Line Chemotherapy: Prognostic Factors and Importance of Second Line Chemotherapy
Background: Limited data exists to support the benefit from second-line chemotherapy in patients with metastatic urothelial carcinoma. Factors that predict survival following progression after first-line platinum-based r...
Priorities in Supportive Care Needs for Non-metastatic Cancer Patients Undergoing Chemotherapy in Iran: The Oncologists’ Perceptions
Background: Cancer patients undergoing chemotherapy have unmet needs. Oncologists play a central role in their supportive treatment. This study aims to describe Iranian oncologists' perceptions in terms of priorities in...
Congenital Giant Melanocytic Nevus with Malignant Melanoma of the Pleura: Do Primary Pleural Melanomas Exist?
Cases of primary pleural and bronchial melanoma have been described in the literature in the absence of melanocytic cells in the pleura and bronchi. We described a case of congenital giant melanocytic nevus that had a pr...